Jose Luis Martin-Ventura

List of Publications by Year
in descending order

154 papers	6,687 citations	47004 47 h-index	79691 73 g-index
163 all docs	163 docs citations	163 times ranked	8837 citing authors

#	Article	IF	Citations
1	Animal Models of Cardiovascular Diseases. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-13.	3.0	287
2	Anti-inflammatory and immunomodulatory effects of statins. Kidney International, 2003, 63, 12-23.	5.2	279
3	Identification by a Differential Proteomic Approach of Heat Shock Protein 27 as a Potential Marker of Atherosclerosis. Circulation, 2004, 110, 2216-2219.	1.6	214
4	Pathology of human plaque vulnerability: Mechanisms and consequences of intraplaque haemorrhages. Atherosclerosis, 2014, 234, 311-319.	0.8	135
5	The CD163-expressing macrophages recognize and internalize TWEAK. Atherosclerosis, 2009, 207, 103-110.	0.8	129
6	Identification of Soluble Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (sTWEAK) as a Possible Biomarker of Subclinical Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 916-922.	2.4	127
7	Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis, 2002, 160, 49-58.	0.8	116
8	Heat shock protein 90 inhibitors attenuate inflammatory responses in atherosclerosis. Cardiovascular Research, 2010, 86, 330-337.	3.8	116
9	Galectinâ€3, a Biomarker Linking Oxidative Stress and Inflammation With the Clinical Outcomes of Patients With Atherothrombosis. Journal of the American Heart Association, 2014, 3, .	3.7	116
10	Leukotriene B4 enhances the activity of nuclear factor-ÂB pathway through BLT1 and BLT2 receptors in atherosclerosis. Cardiovascular Research, 2009, 81, 216-225.	3.8	114
11	Intensive Treatment With Atorvastatin Reduces Inflammation in Mononuclear Cells and Human Atherosclerotic Lesions in One Month. Stroke, 2005, 36, 1796-1800.	2.0	113
12	Suppressors of Cytokine Signaling Modulate JAK/STAT-Mediated Cell Responses During Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 525-531.	2.4	110
13	Proteomic analysis of human vessels: Application to atherosclerotic plaques. Proteomics, 2003, 3, 973-978.	2.2	107
14	Additive Effects of Soluble TWEAK and Inflammation on Mortality in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 110-118.	4.5	106
15	Tumor Necrosis Factorâ€"Like Weak Inducer of Apoptosis (TWEAK) Enhances Vascular and Renal Damage Induced by Hyperlipidemic Diet in ApoE-Knockout Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 2061-2068.	2.4	101
16	Fn14 Is Upregulated in Cytokine-Stimulated Vascular Smooth Muscle Cells and Is Expressed in Human Carotid Atherosclerotic Plaques. Stroke, 2006, 37, 2044-2053.	2.0	95
17	The MIF Receptor CD74 in Diabetic Podocyte Injury. Journal of the American Society of Nephrology: JASN, 2009, 20, 353-362.	6.1	94
18	NF-ÎºB Activation and Fas Ligand Overexpression in Blood and Plaques of Patients With Carotid Atherosclerosis. Stroke, 2004, 35, 458-463.	2.0	91

#	Article	IF	Citations
19	Biological Significance of Decreased HSP27 in Human Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 1337-1343.	2.4	89
20	Overexpression of COX-2, Prostaglandin E Synthase-1 and Prostaglandin E Receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: Regulation by nuclear factor-κB. Atherosclerosis, 2006, 187, 139-149.	0.8	84
21	Quest for Novel Cardiovascular Biomarkers by Proteomic Analysis€. Journal of Proteome Research, 2005, 4, 1181-1191.	3.7	80
22	Soluble TWEAK Plasma Levels as a Novel Biomarker of Endothelial Function in Patients with Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1716-1723.	4.5	78
23	Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: A substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration. American Heart Journal, 2007, 153, 881-888.	2.7	76
24	Identification of Peroxiredoxin-1 as a Novel Biomarker of Abdominal Aortic Aneurysm. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 935-943.	2.4	75
25	ALDH4A1 is an atherosclerosis auto-antigen targeted by protective antibodies. Nature, 2021, 589, 287-292.	27.8	72
26	Proteomic Analysis of Polymorphonuclear Neutrophils Identifies Catalase as a Novel Biomarker of Abdominal Aortic Aneurysm: Potential Implication of Oxidative Stress in Abdominal Aortic Aneurysm Progression. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 3011-3019.	2.4	71
27	ANGPTL4 deficiency in haematopoietic cells promotes monocyte expansion and atherosclerosis progression. Nature Communications, 2016, 7, 12313.	12.8	71
28	Simvastatin reduces NF-κB activity in peripheral mononuclear and in plaque cells of rabbit atheroma more markedly than lipid lowering diet. Cardiovascular Research, 2003, 57, 168-177.	3.8	70
29	Atorvastatin Reduces the Expression of Prostaglandin E2 Receptors in Human Carotid Atherosclerotic Plaques and Monocytic Cells. Journal of Cardiovascular Pharmacology, 2006, 47, 60-69.	1.9	70
30	Improving Metabolite Knowledge in Stable Atherosclerosis Patients by Association and Correlation of GC-MS and ^{1}H NMR Fingerprints. Journal of Proteome Research, 2009, 8, 5580-5589.	3.7	70
31	Possible Role of Parathyroid Hormone–Related Protein as a Proinflammatory Cytokine in Atherosclerosis. Stroke, 2003, 34, 1783-1789.	2.0	67
32	Peripheral Artery Disease Is Associated With a High CD163/TWEAK Plasma Ratio. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1253-1262.	2.4	67
33	HSP90 inhibition by 17-DMAG attenuates oxidative stress in experimental atherosclerosis. Cardiovascular Research, 2012, 95, 116-123.	3.8	67
34	Usefulness of a Combination of Monocyte Chemoattractant Protein-1, Galectin-3, and N-Terminal Probrain Natriuretic Peptide to Predict Cardiovascular Events in Patients With Coronary Artery Disease. American Journal of Cardiology, 2014, 113, 434-440.	1.6	66
35	3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Decrease Fas Ligand Expression and Cytotoxicity in Activated Human T Lymphocytes. Circulation, 2003, 108, 1506-1513.	1.6	64
36	Combined Therapy with Renin-Angiotensin System and Calcium Channel Blockers in Type 2 Diabetic Hypertensive Patients with Proteinuria. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1174-1181.	4.5	63

#	Article	IF	Citations
37	Diagnostic and therapeutic strategies for small abdominal aortic aneurysms. Nature Reviews Cardiology, 2011, 8, 338-347.	13.7	63
38	Targeted gold-coated iron oxide nanoparticles for CD163 detection in atherosclerosis by MRI. Scientific Reports, 2015, 5, 17135.	3.3	62
39	Metabolomics with LC-QTOF-MS Permits the Prediction of Disease Stage in Aortic Abdominal Aneurysm Based on Plasma Metabolic Fingerprint. PLoS ONE, 2012, 7, e31982.	2.5	61
40	Erythrocytes, leukocytes and platelets as a source of oxidative stress in chronic vascular diseases: Detoxifying mechanisms and potential therapeutic options. Thrombosis and Haemostasis, 2012, 108, 435-442.	3.4	58
41	Considering TWEAK as a target for therapy in renal and vascular injury. Cytokine and Growth Factor Reviews, 2009, 20, 251-258.	7.2	57
42	Increased CD74 expression in human atherosclerotic plaques: contribution to inflammatory responses in vascular cells. Cardiovascular Research, 2009, 83, 586-594.	3.8	55
43	Low plasma levels of HSP70 in patients with carotid atherosclerosis are associated with increased levels of proteolytic markers of neutrophil activation. Atherosclerosis, 2007, 194, 334-341.	0.8	54
44	Extracellular Tuning of Mitochondrial Respiration Leads to Aortic Aneurysm. Circulation, 2021, 143, 2091-2109.	1.6	54
45	Increased Soluble Fas Plasma Levels in Subjects at High Cardiovascular Risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 168-174.	2.4	53
46	Increased plasma levels of NGAL, a marker of neutrophil activation, in patients with abdominal aortic aneurysm. Atherosclerosis, 2012, 220, 552-556.	0.8	52
47	Impact of soluble TWEAK and CD163/TWEAK ratio on long-term cardiovascular mortality in patients with peripheral arterial disease. Atherosclerosis, 2011, 219, 892-899.	0.8	50
48	Proteomic Analysis of Intraluminal Thrombus Highlights Complement Activation in Human Abdominal Aortic Aneurysms. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 2013-2020.	2.4	50
49	Local Non-Esterified Fatty Acids Correlate With Inflammation in Atheroma Plaques of Patients With Type 2 Diabetes. Diabetes, 2010, 59, 1292-1301.	0.6	49
50	TWEAK and Fn14. New players in the pathogenesis of atherosclerosis. Frontiers in Bioscience - Landmark, 2007, 12, 3648.	3.0	48
51	Atorvastatin modulates the profile of proteins released by human atherosclerotic plaques. European Journal of Pharmacology, 2007, 562, 119-129.	3.5	48
52	Cardiovascular Risk and Antiangiogenic Therapy for Age-related Macular Degeneration. Survey of Ophthalmology, 2009, 54, 339-348.	4.0	47
53	Biomarcadores en la medicina cardiovascular. Revista Espanola De Cardiologia, 2009, 62, 677-688.	1.2	47
54	CCL20 Is Increased in Hypercholesterolemic Subjects and Is Upregulated By LDL in Vascular Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 2733-2741.	2.4	47

#	Article	IF	Citations
55	HMGB1 Expression and Secretion Are Increased Via TWEAKâ€"Fn14 Interaction in Atherosclerotic Plaques and Cultured Monocytes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 612-620.	2.4	45
56	Oxidative Stress in Human Atherothrombosis: Sources, Markers and Therapeutic Targets. International Journal of Molecular Sciences, 2017, 18, 2315.	4.1	45
57	Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis. Journal of the American College of Cardiology, 2004, 43, 1188-1194.	2.8	42
58	Biology of atherosclerotic plaques: What we are learning from proteomic analysis. Cardiovascular Research, 2006, 72, 18-29.	3.8	42
59	Effect of Intensive Atorvastatin Therapy on Prostaglandin E2 Levels and Metalloproteinase-9 Activity in the Plasma of Patients With Non-ST-Elevation Acute Coronary Syndromeâ€â€Conflicts of interest: Drs. Egido and TuÃ±Ã³n have participated on advisory boards and have been invited speakers for Pfizer.. American Journal of Cardiology, 2008, 102, 12-18.	1.6	42
60	From intraplaque haemorrhages to plaque vulnerability. Journal of Cardiovascular Medicine, 2012, 13, 628-634.	1.5	42
61	Proteomic Strategies in the Search of New Biomarkers in Atherothrombosis. Journal of the American College of Cardiology, 2010, 55, 2009-2016.	2.8	41
62	ApoA-I/HDL-C levels are inversely associated with abdominal aortic aneurysm progression. Thrombosis and Haemostasis, 2015, 113, 1335-1346.	3.4	41
63	TWEAK/Fn14 interaction promotes oxidative stress through NADPH oxidase activation in macrophages. Cardiovascular Research, 2015, 108, 139-147.	3.8	40
64	APOA1 oxidation is associated to dysfunctional high-density lipoproteins in human abdominal aortic aneurysm. EBioMedicine, 2019, 43, 43-53.	6.1	40
65	Genetic deletion or <scp>TWEAK</scp> blocking antibody administration reduce atherosclerosis and enhance plaque stability in mice. Journal of Cellular and Molecular Medicine, 2014, 18, 721-734.	3.6	39
66	Red Blood Cells and Hemoglobin in Human Atherosclerosis and Related Arterial Diseases. International Journal of Molecular Sciences, 2020, 21, 6756.	4.1	39
67	Plasma Concentration of Heat Shock Protein 27 and Risk of Cardiovascular Disease: A Prospective, Nested Case-Control Study. Clinical Chemistry, 2008, 54, 139-146.	3.2	38
68	Lipocalin-2 deficiency or blockade protects against aortic abdominal aneurysm development in mice. Cardiovascular Research, 2016, 111, 262-273.	3.8	38
69	TWEAK-Fn14 interaction enhances plasminogen activator inhibitor 1 and tissue factor expression in atherosclerotic plaques and in cultured vascular smooth muscle cells. Cardiovascular Research, 2011, 89, 225-233.	3.8	37
70	Down-regulation of Fibulin-5 is associated with aortic dilation: role of inflammation and epigenetics. Cardiovascular Research, 2016, 110, 431-442.	3.8	36
71	Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk. European Journal of Pharmacology, 2008, 586, 259-265.	3.5	35
72	A Single In-Vial Dual Extraction Strategy for the Simultaneous Lipidomics and Proteomics Analysis of HDL and LDL Fractions. Journal of Proteome Research, 2016, 15, 1762-1775.	3.7	35

#	Article	IF	Citations
73	Thioredoxin-1/peroxiredoxin-1 as sensors of oxidative stress mediated by NADPH oxidase activity in atherosclerosis. Free Radical Biology and Medicine, 2015, 86, 352-361.	2.9	34
74	RNA binding protein HuR regulates the expression of ABCA1. Journal of Lipid Research, 2014, 55, 1066-1076.	4.2	33
75	Study of the capillary electrophoresis profile of intact α-1-acid glycoprotein isoforms as a biomarker of atherothrombosis. Analyst, The, 2011, 136, 816-822.	3.5	32
76	Heat-shock proteins in cardiovascular disease. Advances in Clinical Chemistry, 2011, 54, 1-43.	3.7	32
77	Complement C5 Protein as a Marker of Subclinical Atherosclerosis. Journal of the American College of Cardiology, 2020, 75, 1926-1941.	2.8	32
78	Metabolites Secreted by Human Atherothrombotic Aneurysms Revealed through a Metabolomic Approach. Journal of Proteome Research, 2011, 10, 1374-1382.	3.7	31
79	HMG-CoA Reductase Inhibitors Reduce IκB Kinase Activity Induced by Oxidative Stress in Monocytes and Vascular Smooth Muscle Cells. Journal of Cardiovascular Pharmacology, 2005, 45, 468-475.	1.9	30
80	From tissue iron retention to low systemic haemoglobin levels, new pathophysiological biomarkers of human abdominal aortic aneurysm. Thrombosis and Haemostasis, 2014, 112, 87-95.	3.4	30
81	Induction of Macrophage Chemotaxis by Aortic Extracts from Patients with Marfan Syndrome Is Related to Elastin Binding Protein. PLoS ONE, 2011, 6, e20138.	2.5	30
82	Quantitative HDL Proteomics Identifies Peroxiredoxin-6 as a Biomarker of Human Abdominal Aortic Aneurysm. Scientific Reports, 2016, 6, 38477.	3.3	29
83	Role of complement system in pathological remodeling of the vascular wall. Molecular Immunology, 2019, 114, 207-215.	2.2	29
84	Ethanol beverages containing polyphenols decrease nuclear factor kappa-B activation in mononuclear cells and circulating MCP-1 concentrations in healthy volunteers during a fat-enriched diet. Atherosclerosis, 2007, 192, 335-341.	0.8	28
85	Biomarkers in Cardiovascular Medicine. Revista Espanola De Cardiologia (English Ed), 2009, 62, 677-688.	0.6	28
86	Assessment of Biomarkers and Predictive Model for Short-term Prospective Abdominal Aortic Aneurysm Growth—A Pilot Study. Annals of Vascular Surgery, 2014, 28, 1642-1648.	0.9	27
87	Proteomic and Metabolomic Profiles in Atherothrombotic Vascular Disease. Current Atherosclerosis Reports, 2010, 12, 202-208.	4.8	26
88	Label-free quantitative proteomic analysis of human plasma-derived microvesicles to find protein signatures of abdominal aortic aneurysms. Proteomics - Clinical Applications, 2014, 8, 620-625.	1.6	26
89	Targeted and non-targeted metabolic time trajectory in plasma of patients after acute coronary syndrome. Journal of Pharmaceutical and Biomedical Analysis, 2011, 56, 343-351.	2.8	24
90	Metabolomic study of plasma of patients with abdominal aortic aneurysm. Analytical and Bioanalytical Chemistry, 2012, 403, 1651-1660.	3.7	22

#	Article	IF	Citations
91	Hemoglobin induces monocyte recruitment and CD163-macrophage polarization in abdominal aortic aneurysm. International Journal of Cardiology, 2015, 201, 66-78.	1.7	22
92	Combination of biomarkers of vascular calcification and sTWEAK to predict cardiovascular events in chronic kidney disease. Atherosclerosis, 2018, 270, 13-20.	0.8	22
93	Soluble TWEAK is associated with atherosclerotic burden in patients with chronic kidney disease. Journal of Nephrology, 2013, 26, 1105-1113.	2.0	22
94	Characterization of the Human Atheroma Plaque Secretome by Proteomic Analysis. , 2007, 357, 141-150.		21
95	Tumor Necrosis Factor–Like Weak Inducer of Apoptosis or Fn14 Deficiency Reduce Elastase Perfusion–Induced Aortic Abdominal Aneurysm in Mice. Journal of the American Heart Association, 2014, 3, .	3.7	21
96	A major role of TWEAK/Fn14 axis as a therapeutic target for post-angioplasty restenosis. EBioMedicine, 2019, 46, 274-289.	6.1	21
97	Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (TWEAK)/Fibroblast Growth Factor-Inducible 14 (Fn14) Axis in Cardiovascular Diseases: Progress and Challenges. Cells, 2020, 9, 405.	4.1	21
98	Soluble Fas ligand plasma levels are associated with forearm reactive hyperemia in subjects with coronary artery disease. Atherosclerosis, 2008, 201, 407-412.	0.8	20
99	Treatment with amlodipine and atorvastatin has additive effect on blood and plaque inflammation in hypertensive patients with carotid atherosclerosis. Kidney International, 2008, 74, S71-S74.	5.2	20
100	Fisiopatología del aneurisma de aorta abdominal: biomarcadores y nuevas dianas terapéuticas. Clínica E Investigación En Arteriosclerosis, 2019, 31, 166-177.	0.8	20
101	Soluble TWEAK and Major Adverse Cardiovascular Events in Patients with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 413-422.	4.5	19
102	Role of Extracellular Vesicles as Potential Diagnostic and/or Therapeutic Biomarkers in Chronic Cardiovascular Diseases. Frontiers in Cell and Developmental Biology, 2022, 10, 813885.	3.7	19
103	Soluble TWEAK and atheromatosis progression in patients with chronic kidney disease. Atherosclerosis, 2017, 260, 130-137.	0.8	18
104	Galectin-1 prevents pathological vascular remodeling in atherosclerosis and abdominal aortic aneurysm. Science Advances, 2022, 8, eabm7322.	10.3	18
105	Atorvastatin decreases elevated soluble CD40L in subjects at high cardiovascular risk. Atorvastatin on inflammatory markers study: a substudy of ACTFAST. Kidney International, 2008, 74, S60-S63.	5.2	17
106	Vascular proteomics and the discovery process of clinical biomarkers: The case of TWEAK. Proteomics - Clinical Applications, 2011, 5, 281-288.	1.6	17
107	Proteomic approach in the search of new cardiovascular biomarkers. Kidney International, 2005, 68, S103-S107.	5.2	16
108	The Prognostic Value of High-Sensitive Troponin I in Stable Coronary Artery Disease Depends on Age and Other Clinical Variables. Cardiology, 2015, 132, 1-8.	1.4	15

#	Article	IF	Citations
109	Soluble TWEAK levels predict the presence of carotid atherosclerotic plaques in subjects free from clinical cardiovascular diseases. Atherosclerosis, 2015, 239, 358-363.	0.8	15
110	Differential profile in inflammatory and mineral metabolism biomarkers in patients with ischemic heart disease without classical coronary risk factors. Journal of Cardiology, 2015, 66, 22-27.	1.9	15
111	Arachidonic Acid, but Not Omegaâ€3 Index, Relates to the Prevalence and Progression of Abdominal Aortic Aneurysm in a Populationâ€Based Study of Danish Men. Journal of the American Heart Association, 2018, 7, .	3.7	15
112	Galectin-3 is Associated with Cardiovascular Events in Post-Acute Coronary Syndrome Patients with Type-2 Diabetes. Journal of Clinical Medicine, 2020, 9, 1105.	2.4	15
113	N-Terminal Pro-Brain Natriuretic Peptide Is Associated with a Future Diagnosis of Cancer in Patients with Coronary Artery Disease. PLoS ONE, 2015, 10, e0126741.	2.5	15
114	Common pathways of hypercholesterolemia and hypertension leading to atherothrombosis: the need for a global approach in the management of cardiovascular risk factors. Vascular Health and Risk Management, 2007, 3, 521-6.	2.3	15
115	Mechanisms of action of statins in stroke. Expert Opinion on Therapeutic Targets, 2007, 11, 273-278.	3.4	14
116	Trail and vascular injury. Frontiers in Bioscience - Landmark, 2007, 12, 3656.	3.0	14
117	TWEAK blockade decreases atherosclerotic lesion size and progression through suppression of STAT1 signaling in diabetic mice. Scientific Reports, 2017, 7, 46679.	3.3	14
118	Protective effect of suppressor of cytokine signalling 1â€based therapy in experimental abdominal aortic aneurysm. British Journal of Pharmacology, 2021, 178, 564-581.	5.4	14
119	MCP-1 Predicts Recurrent Cardiovascular Events in Patients with Persistent Inflammation. Journal of Clinical Medicine, 2021, 10, 1137.	2.4	14
120	Proteomics in atherothrombosis: a future perspective. Expert Review of Proteomics, 2007, 4, 249-260.	3.0	13
121	Potential role of insulin receptor isoforms and IGF receptors in plaque instability of human and experimental atherosclerosis. Cardiovascular Diabetology, 2018, 17, 31.	6.8	13
122	Impaired HDL (High-Density Lipoprotein)-Mediated Macrophage Cholesterol Efflux in Patients With Abdominal Aortic Aneurysmâ€"Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 2750-2754.	2.4	13
123	CD163 deficiency increases foam cell formation and plaque progression in atherosclerotic mice. FASEB Journal, 2020, 34, 14960-14976.	0.5	13
124	Proteomics in atherosclerosis. Current Atherosclerosis Reports, 2008, 10, 209-215.	4.8	12
125	IgG Anti-High Density Lipoprotein Antibodies Are Elevated in Abdominal Aortic Aneurysm and Associated with Lipid Profile and Clinical Features. Journal of Clinical Medicine, 2020, 9, 67.	2.4	12
126	Plasma Levels of Monocyte Chemoattractant Protein-1, n-Terminal Fragment of Brain Natriuretic Peptide and Calcidiol Are Independently Associated with the Complexity of Coronary Artery Disease. PLoS ONE, 2016, 11, e0152816.	2.5	12

#	ARTICLE	IF	CITATIONS
127	Vascular Protection of Dual Therapy (Atorvastatin-Amlodipine) in Hypertensive Patients. Journal of the American Society of Nephrology: JASN, 2006, 17, S189-S193.	6.1	11
128	Label-free proteomic analysis of red blood cell membrane fractions from abdominal aortic aneurysm patients. Proteomics - Clinical Applications, 2014, 8, 626-630.	1.6	11
129	Proteomics and metabolomics in biomarker discovery for cardiovascular diseases: progress and potential. Expert Review of Proteomics, 2016, 13, 857-871.	3.0	11
130	Parathormone levels add prognostic ability to N-terminal pro-brain natriuretic peptide in stable coronary patients. ESC Heart Failure, 2021, 8, 2713-2722.	3.1	10
131	Statin Use in Aortic Aneurismal Disease to Prevent Progression and Cardiovascular Events: Review of Experimental and Clinical Data. Current Vascular Pharmacology, 2013, 11, 299-304.	1.7	10
132	Characterization of HSP27 Phosphorylation Sites in Human Atherosclerotic Plaque Secretome. , 2007, 357, 151-164.		9
133	Cell Stress Proteins in Atherothrombosis. Oxidative Medicine and Cellular Longevity, 2012, 2012, 1-10.	4.0	9
134	Vascular proteomics, a translational approach: from traditional to novel proteomic techniques. Expert Review of Proteomics, 2009, 6, 461-464.	3.0	8
135	Oxidative Stress in Cardiovascular Pathologies: Genetics, Cellular, and Molecular Mechanisms and Future Antioxidant Therapies. Oxidative Medicine and Cellular Longevity, 2012, 2012, 1-3.	4.0	8
136	LDL induces parathyroid hormone-related protein expression in vascular smooth muscle cells: Modulation by simvastatin. Atherosclerosis, 2008, 198, 264-271.	0.8	7
137	Monocyte Chemoattractant Protein-1 Is an Independent Predictor of Coronary Artery Ectasia in Patients with Acute Coronary Syndrome. Journal of Clinical Medicine, 2020, 9, 3037.	2.4	7
138	Statins in Hypertensive Patients. Drugs, 2004, 64, 61-67.	10.9	5
139	The Proteomic Approach in the Development of Prognostic Biomarkers in Atherothrombosis. Recent Patents on Cardiovascular Drug Discovery, 2009, 4, 25-30.	1.5	5
140	Intensive treatment with statins and the progression of cardiovascular diseases: the beginning of a new era?. Nephrology Dialysis Transplantation, 2004, 19, 2696-2699.	0.7	4
141	Proteomic Analysis of Circulating Monocytes Identifies Cathepsin D as A Potential Novel Plasma Marker of Acute Coronary Syndromes. Clinical Medicine Cardiology, 2008, 2, CMC.S654.	0.1	3
142	Identification of Novel Biomarkers of Abdominal Aortic Aneurysms by 2D-DIGE and MALDI-MS from AAA-Thrombus-Conditioned Media. Methods in Molecular Biology, 2013, 1000, 91-101.	0.9	3
143	Pathophysiology of abdominal aortic aneurysm: biomarkers and novel therapeutic targets. Clínica E Investigación En Arteriosclerosis (English Edition), 2019, 31, 166-177.	0.2	3
144	Malondialdehyde-modified HDL particles elicit a specific IgG response in abdominal aortic aneurysm. Free Radical Biology and Medicine, 2021, 174, 171-181.	2.9	3

#	Article	IF	Citations
145	Inflammatory biomarkers and statins. Drugs of Today, 2005, 41, 171.	2.4	3
146	Unraveling Biomarkers of Abdominal Aortic Aneurisms by iTRAQ Analysis of Depleted Plasma. Methods in Molecular Biology, 2013, 1000, 157-166.	0.9	2
147	Macrophage Cholesterol Efflux Downregulation Is Not Associated with Abdominal Aortic Aneurysm (AAA) Progression. Biomolecules, 2020, 10, 662.	4.0	2
148	N-Terminal Pro-Brain Natriuretic Peptide Plasma Levels Are Associated with Intermediate-Term Follow-Up Cancer in Coronary Patients. Journal of Clinical Medicine, 2021, 10, 4042.	2.4	2
149	Combined Immunoglobulin Free Light Chains Are Novel Predictors of Cardiovascular Events in Patients With Abdominal Aortic Aneurysm. European Journal of Vascular and Endovascular Surgery, 2022, 63, 751-758.	1.5	2
150	Impacto de la función renal en el valor pronóstico del metabolismo mineral en pacientes con cardiopatía isquémica crónica. Clínica E Investigación En Arteriosclerosis, 2022, 34, 1-9.	0.8	1
151	NT-proBNP Levels Influence the Prognostic Value of Mineral Metabolism Biomarkers in Coronary Artery Disease. Journal of Clinical Medicine, 2022, 11, 4153.	2.4	1
152	Respuesta. Revista Espanola De Cardiologia, 2009, 62, 1342-1343.	1.2	0
153	Vascular Proteomics. , 2016, , 105-122.		0
154	Impact of renal function on the prognostic value of mineral metabolism in patients with chronic ischaemic heart disease patients with chronic ischaemic heart disease. Clínica E Investigación En Arteriosclerosis (English Edition), 2022, , .	0.2	0